Clinical trials in CIS countries 2012: Russia, Ukraine, Belarus and Georgia, Development forecasts for 2012-2014 is a new PMR report focused on clinical trial operating conditions in selected CIS countries, as well as statistical data and analysis on the existing market and projections for development until 2014. This document appears at a most relevant time, since pharmaceutical companies are eager to bring new drugs to market in order to replace earnings as major patents near their expiration dates.
Readers benefit from analysis and discussion of specific prospects and pitfalls of the marketplace, as well as representation of the current environment in each country: the number, type, registration waiting period and comparison of variation of those regulations in each of the covered CIS countries. Markets are compared in terms of volume, value, time constraint and other common circumstances that tend to affect profitability.
The report pays ample attention to the top companies participating in clinical trials programs across Russia, Ukraine, Belarus and Georgia; it provides specific detail on total trials, types of drugs and phases of current trials as well as their locations. It also presents in depth profiles of the region’s largest CROs and their sponsors, and describes activity in their main countries of operation.
This exciting new report looks to the future, including reliable forecasts on topics such as the value and number of clinical trials that will be conducted going forward through 2014. Discussions of impending changes to the legislative environment for Clinical Trials in the covered countries are included, along with analysis of recent trends and their potential effects.
Clinical trials in CIS countries 2012: Russia, Ukraine, Belarus and Georgia, Development forecasts for 2012-2014 provides a unique compilation of information that clarifies complex conditions of the current market and projects opportunity for the future of the industry.